Study of breast cancer in younger and older women
Part of Cancer, Skin clinical trials.
This study looks at breast cancer in women diagnosed at or before age 45 or at or after age 55. Researchers want to understand how the reproductive cycle might affect how aggressive the cancer is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with breast cancer at age 45 or younger, or at age 55 or older.
- Your cancer is triple-negative or hormone receptor positive and HER2 negative.
- A sample of your tumor from diagnosis must be available for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at differences between younger and older breast cancer patients to better understand the disease. If you had breast cancer between the ages of 18 and 75 and were treated in a Chinese hospital from 2000 to 2024, you might be able to help.
This study looks at young women with early-stage breast cancer who are premenopausal (still having periods) and have a low-to-intermediate Oncotype score, to see how well hormone therapy works. It aims to understand if current treatment decisions are appropriate.
This study looks at how age-related changes in your blood might affect how well your breast cancer treatment works. It includes people with hormone receptor-positive, HER2-negative breast cancer that has not spread to distant organs.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This study looks back at treatments given to people with triple-negative or HER2-positive early breast cancer between 2016 and 2021. It aims to understand how treatment approaches have changed over time.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.